{"id":473470,"date":"2021-04-08T06:48:28","date_gmt":"2021-04-08T10:48:28","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=473470"},"modified":"2021-04-08T06:48:28","modified_gmt":"2021-04-08T10:48:28","slug":"lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\/","title":{"rendered":"Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients"},"content":{"rendered":"
\n

– Randomized, double-blind, placebo-controlled study of 1,525 patients did not meet statistical significance on primary endpoint (progression to non-invasive ventilation or invasive mechanical ventilation or death)<\/h2>\n

– Data showed 38% reduction in mortality by Day 28 (nominal p-value=0.0018) in patients treated with baricitinib in addition to standard of care, including corticosteroids and remdesivir<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n INDIANAPOLIS<\/span>, April 8, 2021<\/span> \/PRNewswire\/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical significance on the\u00a0primary endpoint, which was defined as a difference in the proportion of participants progressing to the first occurrence of non-invasive ventilation including high flow oxygen or invasive mechanical ventilation including extracorporeal membrane oxygenation (ECMO) or death by Day 28. Baricitinib-treated patients were 2.7 percent less likely than those receiving standard of care to progress to ventilation (non-invasive or mechanical) or death, a difference that was not statistically significant (odds ratio [OR]: 0.85; 95% CI 0.67, 1.08; p=0.1800).\u00a0<\/p>\n

In COV-BARRIER, treatment with baricitinib in addition to SoC (which included 79% receiving corticosteroids and 19% receiving remdesivir, with some receiving both) resulted in a significant reduction (nominal p-value=0.0018) in death from any cause by 38 percent (n\/N: 62\/764 [8.1%] baricitinib, 100\/761 [13.1%] placebo; hazard ratio [HR]: 0.57; 95% CI: 0.41, 0.78) by Day 28. A numerical reduction in mortality was observed for all baseline severity subgroups of baricitinib-treated patients and was most pronounced for patients receiving non-invasive mechanical ventilation at baseline (17.5% versus 29.4% for baricitinib plus SoC versus SoC; hazard ratio [HR]: 0.52; 95% CI: 0.33, 0.80; nominal p-value=0.0065). A reduction in mortality was also seen for the pre-specified subgroups of patients being treated with or without corticosteroids at baseline.\u00a0 <\/p>\n

“There remains a driving unmet need for treatments with the potential to further decrease mortality for COVID-19 patients,” said co-primary investigator E. Wesley Ely<\/span>, M.D., MPH, professor of medicine and co-director of the Critical Illness, Brain Dysfunction, and Survivorship (CIBS) Center at Vanderbilt University<\/span> Medical Center. “While COV-BARRIER did not hit the primary endpoint based on stages of disease progression, the data show that baricitinib meaningfully reduced the risk of mortality above and beyond the recommended standard of care, without additional safety risks. These important findings advance our pursuit of treatment options to save lives in hospitalized COVID-19 patients.”<\/p>\n

The frequency of adverse events and serious adverse events were generally similar in the baricitinib (44.5% and 14.7%, respectively) and placebo (44.4% and 18.0%, respectively) groups. Serious infections and venous thromboembolism (VTE) occurred in 8.5 percent and 2.7 percent of patients treated with baricitinib, respectively, versus 9.8 percent and 2.5 percent of patients treated with placebo. No new safety signals potentially related to the use of baricitinib were identified. <\/p>\n

Lilly intends to publish detailed results of this study in a peer-reviewed journal in the coming months. Lilly will share the data from COV-BARRIER with regulatory authorities in the U.S., European Union and other geographies to evaluate next steps for baricitinib for the treatment of hospitalized COVID-19 patients. <\/p>\n

“Since the beginning of the pandemic, we have worked to expand the science behind COVID-19 therapies,” said Ilya Yuffa<\/span>, senior vice president and president of Lilly Bio-Medicines. “Even though the study did not show a statistically-significant benefit on the primary endpoint, this trial showed the largest effect reported to date for reduction in mortality observed for this patient population with COVID-19. As there remains an urgent need to reduce COVID-related deaths in hospitalized patients, we hope these results will provide further understanding and support for baricitinib’s potential role in treatment on top of the current standard of care.”<\/p>\n

COV-BARRIER (NCT04421027)\u00a0is the first global, randomized, double-blind, placebo-controlled study to assess baricitinib versus placebo in patients hospitalized with COVID-19 receiving SoC which could include corticosteroids, antimalarials, antivirals, and\/or azithromycin. This Phase 3 study of 1,525 patients began in June 2020<\/span> and enrolled hospitalized patients who did not require supplemental oxygen (ordinal scale [OS] 4), required supplemental oxygen (OS 5) or high-flow oxygen\/non-invasive ventilation (OS 6). Patients were also required to have at least one increased marker of inflammation, an indicator of risk of disease progression. All patients were treated with SoC per local clinical practice including\u00a079 percent receiving corticosteroids (with 91% of those patients receiving dexamethasone) and 19 percent receiving remdesivir at baseline, with some receiving both. Patients were randomized 1:1 to baricitinib 4 mg or placebo for up to 14 days or until discharge from the hospital. The study was global and included diverse patients from several countries with high prevalence of COVID-19 hospitalizations \u2013 the U.S., Brazil<\/span>, Mexico<\/span>, Argentina<\/span>, Russia<\/span>, India<\/span>, UK, Spain<\/span>, Italy<\/span>, Germany<\/span>, Japan<\/span> and Korea. An addendum to the study was initiated in December 2020<\/span> to include mechanically ventilated (OS 7) patients at baseline and is currently enrolling. <\/p>\n

The COV-BARRIER trial was designed to complement the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). ACTT-2\u00a0began in May 2020<\/span> and has published results<\/a> from 1,033 patients. Patients who received baricitinib in combination with remdesivir had a shorter median time to recovery compared to patients who received remdesivir alone. In ACTT-2, there was a significant reduction in the proportion of patients progressing to noninvasive ventilation, invasive mechanical ventilation or death, in the baricitinib plus remdesivir group compared to remdesivir. A numerical decrease in mortality risk through Day 29 was observed in patients treated with baricitinib plus remdesivir compared to remdesivir.<\/p>\n

“While the trend observed for the primary endpoint was not significant, the demonstration of a potential effect on mortality is a clinically important finding. This effect on mortality was seen with or without corticosteroids and\/or remdesivir at the time of enrollment,” said Vincent C. Marconi<\/span>, M.D., professor of medicine and global health at Emory University School of Medicine<\/span> and Emory’s<\/span>Rollins School<\/span> of Public Health, a co-principal investigator of COV-BARRIER and a co-investigator on the ACTT-2 study. “These results \u2013 along with those from the NIAID-sponsored ACTT-2 study evaluating baricitinib in combination with remdesivir \u2013 add to the growing body of data supporting the use of baricitinib in certain hospitalized patients with COVID-19.”<\/p>\n

Additional research is ongoing to further evaluate the potential role of baricitinib in COVID-19, including NIAID’s ACTT-4 trial (evaluating the efficacy and safety of baricitinib or dexamethasone in combination with remdesivir in hospitalized adults with COVID-19 on supplemental oxygen), the RECOVERY trial in the UK and several investigator-initiated trials.\u00a0 <\/p>\n

An emergency use authorization (EUA) was issued by the U.S. Food and Drug Administration (FDA) on Nov. 19, 2020<\/span> for baricitinib in combination with remdesivir in hospitalized patients with COVID-19 requiring supplemental oxygen, invasive mechanical ventilation, or ECMO. Please see below for important warnings and information about the authorized use of baricitinib in the U.S. \u00a0More than 200,000 patients globally are estimated to have been treated with baricitinib for COVID-19. <\/p>\n

Baricitinib, an oral JAK inhibitor, was\u00a0discovered by\u00a0Incyte\u00a0and licensed to Lilly.\u00a0It is approved and commercially available as OLUMIANT in the U.S. and more than 70 countries as a treatment for adults with moderate to severe active rheumatoid arthritis (RA) and in the European Union and Japan<\/span> for the treatment of adult patients with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.<\/p>\n

\n Authorized Use Under the EUA and Important Safety Information for baricitinib (in\u00a0the United States<\/span>) for COVID-19<\/b>
\n
Baricitinib is authorized for use under an Emergency Use Authorization (EUA) in combination with remdesivir, for treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID-19) in hospitalized adults and pediatric patients 2 years of age or older, requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).\u00a0<\/p>\n

Baricitinib\u00a0has not been approved for the treatment of COVID-19, but\u00a0has been authorized for emergency use by the FDA. Baricitinib is authorized under an EUA only for the duration of the declaration that circumstances exist justifying the authorization of the EUA of baricitinib under Section 564(b)(1) of the Act, 21 U.S.C. \u00a7 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.\u00a0\u00a0<\/p>\n

For information on the authorized use of baricitinib and mandatory requirements under the EUA, please review the\u00a0FDA Letter of Authorization<\/a>,\u00a0Fact Sheet for Healthcare Providers<\/a>\u00a0and Fact Sheet for Patients, Parents and Caregivers (English<\/a>;\u00a0Spanish<\/a>).\u00a0<\/p>\n

\n Important Safety Information\u00a0about baricitinib for COVID-19<\/b>\u00a0
The following provides essential safety information on the unapproved use of baricitinib under the Emergency Use Authorization.\u00a0<\/p>\n

\n Warnings<\/b>\u00a0<\/p>\n

\n Serious Infections:<\/b>\u202fSerious infections have occurred in patients receiving baricitinib. Avoid the use of baricitinib with known active tuberculosis. Consider if the potential benefits outweigh the potential risks of baricitinib treatment in patients with active serious infections other than COVID-19 or chronic\/recurrent infections.\u00a0<\/p>\n

\n Thrombosis:<\/b>\u202fIn hospitalized patients with COVID-19, prophylaxis for venous thromboembolism is recommended unless contraindicated. If clinical features of deep vein thrombosis or pulmonary embolism occur, patients should be evaluated promptly and treated appropriately.\u00a0<\/p>\n

\n Abnormal Laboratory Values:<\/b>\u202fEvaluate at baseline and thereafter according to local patient management practice. Monitor closely when treating patients with abnormal baseline and post-baseline laboratory values. Follow dose adjustments as recommended in the Fact Sheet for Healthcare Providers for patients with abnormal renal,\u00a0hematological\u00a0and hepatic laboratory values. Manage patients according to routine clinical guidelines.\u00a0<\/p>\n

\n Hypersensitivity:<\/b>
\n \u202f<\/b>If a serious hypersensitivity occurs, discontinue baricitinib while evaluating the potential causes of the reaction.\u00a0<\/p>\n

See\u202fWarnings and Precautions<\/b>\u202fin the FDA-approved full Prescribing Information for additional information on risks associated with longer-term treatment with baricitinib.\u00a0<\/p>\n

\n Serious Side Effects<\/b>: Serious venous thrombosis, including pulmonary embolism, and serious infections have been observed in COVID-19 patients treated with baricitinib and are known adverse drug reactions of baricitinib.\u00a0<\/p>\n

There are limited clinical data available for baricitinib use in coronavirus 2019 (COVID-19). Additional information regarding baricitinib for its FDA-approved indication, including safety information, may be\u00a0found in the full\u202fPrescribing Information<\/a>, including Boxed Warning about Serious Infections, Malignancies, and Thrombosis, and\u202fMedication Guide<\/a>.\u00a0<\/p>\n

\n Use in Specific Populations<\/b>\u00a0<\/p>\n

\n Pregnancy<\/b>: Baricitinib should be used during pregnancy only if the potential benefit justifies the potential risk for the mother and the fetus.\u00a0<\/p>\n

\n Renal Impairment<\/b>: There are limited data for baricitinib in patients with severe renal impairment.\u00a0Baricitinib\u00a0is not recommended for patients who are on dialysis, have end-stage renal\u00a0disease, or\u00a0have acute kidney injury.\u00a0<\/p>\n

\n Hepatic Impairment<\/b>: Baricitinib has not been studied in patients with severe hepatic impairment. Baricitinib should only be used in patients with severe hepatic impairment if the potential benefit outweighs the potential risk.\u00a0<\/p>\n

BC HCP EUA ISI 19NOV2020<\/p>\n

\n About\u00a0Lilly’s COVID-19 Efforts
<\/b>Lilly\u00a0is bringing the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world. Existing\u00a0Lilly\u00a0medicines are being studied to understand their potential in treating complications of COVID-19, and the company is collaborating with partner companies to discover and develop novel antibody treatments for COVID-19.\u00a0Lilly\u00a0is testing both single antibody therapy as well as combinations of antibodies as potential therapeutics for COVID-19. Click\u00a0here<\/a>\u00a0for resources related to\u00a0Lilly’s COVID-19 efforts and\u00a0here<\/a>\u00a0for baricitinib’s EUA.<\/p>\n

\n About OLUMIANT\u00a0\u00ae <\/sup>(baricitinib)
<\/b>OLUMIANT is a once-daily, oral JAK inhibitor approved in the\u00a0U.S.\u00a0and more than 70 countries as a treatment for adults with moderate to severe rheumatoid arthritis and was recently approved in the\u00a0European Union\u00a0and Japan<\/span> for the treatment of adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy. The\u00a0U.S.\u00a0FDA-approved labeling for Olumiant includes a Boxed Warning for Serious Infections, Malignancy, and Thrombosis. See the full Prescribing Information\u00a0here<\/a>. Baricitinib is also being investigated in alopecia areata (AA), juvenile idiopathic arthritis (JIA) and systematic lupus erythematosus (SLE).<\/p>\n

In\u00a0December 2009,\u00a0Lilly\u00a0and\u00a0Incyte\u00a0announced an exclusive worldwide license and collaboration agreement for the development and commercialization of baricitinib and certain follow-on compounds for patients with inflammatory and autoimmune diseases.<\/p>\n

\n About\u00a0Eli Lilly and Company\u00a0
<\/b>Lilly\u00a0is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe,\u00a0Lilly\u00a0employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about\u00a0Lilly, please visit us at\u00a0lilly.com<\/a>\u00a0and\u00a0lilly.com\/newsroom<\/a>.\u00a0\u00a0P-LLY<\/p>\n

\n About\u00a0Incyte\u00a0
<\/b>Incyte\u00a0is a\u00a0Wilmington,\u00a0Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on\u00a0Incyte, please visit\u00a0Incyte.com<\/a>\u00a0and follow\u00a0@Incyte<\/a>.<\/p>\n

\n Cautionary Statement Regarding Forward-Looking Statements
<\/b>
\n This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about OLUMIANT (baricitinib) as a potential treatment for patients with COVID-19 and reflects\u00a0Lilly’s and\u00a0Incyte’s\u00a0current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of research, development and commercialization. Among other things, there can be no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with the results to date, that OLUMIANT will receive additional regulatory approvals or authorizations or be commercially successful, or that OLUMIANT will be safe and effective as a treatment for COVID-19. For further discussion of these and other risks and uncertainties, see\u00a0Lilly’s and\u00a0Incyte’s\u00a0most recent respective Form 10-K and Form 10-Q filings with the\u00a0United States Securities and Exchange Commission. Except as required by law,\u00a0Lilly\u00a0and\u00a0Incyte\u00a0undertake no duty to update forward-looking statements to reflect events after the date of this release.<\/i>\n <\/p>\n

\n\n\n\n\n\n
\n

\n Refer to: <\/span>\n <\/p>\n<\/td>\n

\n

\n Kristen Basu; basu_kristen_porter@lilly.com<\/a>; +1-317-447-2199 (Lilly media)<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n Kevin Hern; hern_kevin_r@lilly.com<\/a>; +1-317-277-1838 (Lilly investors)<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n Catalina Loveman; cloveman@incyte.com<\/a>; +1-302-498-6171 (Incyte media)<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n Christine Chiou; cchiou@incyte.com<\/a>; +1-302-274-4773 (Incyte investors)<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\u00a0<\/p>\n

\n

\n
\n \"Eli
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\u00a0<\/p>\n

\n

\n
\n \"Incyte
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients-301264421.html<\/a><\/p>\n

SOURCE Eli Lilly and Company<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

– Randomized, double-blind, placebo-controlled study of 1,525 patients did not meet statistical significance on primary endpoint (progression to non-invasive ventilation or invasive mechanical ventilation or death) – Data showed 38% reduction in mortality by Day 28 (nominal p-value=0.0018) in patients treated with baricitinib in addition to standard of care, including corticosteroids and remdesivir PR Newswire INDIANAPOLIS, April 8, 2021 \/PRNewswire\/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical significance on the\u00a0primary endpoint, which was defined as a difference in the proportion of participants progressing to the first occurrence … <\/p>\n

Continue reading “Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-473470","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"– Randomized, double-blind, placebo-controlled study of 1,525 patients did not meet statistical significance on primary endpoint (progression to non-invasive ventilation or invasive mechanical ventilation or death) – Data showed 38% reduction in mortality by Day 28 (nominal p-value=0.0018) in patients treated with baricitinib in addition to standard of care, including corticosteroids and remdesivir PR Newswire INDIANAPOLIS, April 8, 2021 \/PRNewswire\/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical significance on the\u00a0primary endpoint, which was defined as a difference in the proportion of participants progressing to the first occurrence … Continue reading "Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-08T10:48:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/661014\/Eli_Lilly_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients\",\"datePublished\":\"2021-04-08T10:48:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\\\/\"},\"wordCount\":2327,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/661014\\\/Eli_Lilly_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\\\/\",\"name\":\"Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/661014\\\/Eli_Lilly_Logo.jpg\",\"datePublished\":\"2021-04-08T10:48:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/661014\\\/Eli_Lilly_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/661014\\\/Eli_Lilly_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\/","og_locale":"en_US","og_type":"article","og_title":"Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients - Market Newsdesk","og_description":"– Randomized, double-blind, placebo-controlled study of 1,525 patients did not meet statistical significance on primary endpoint (progression to non-invasive ventilation or invasive mechanical ventilation or death) – Data showed 38% reduction in mortality by Day 28 (nominal p-value=0.0018) in patients treated with baricitinib in addition to standard of care, including corticosteroids and remdesivir PR Newswire INDIANAPOLIS, April 8, 2021 \/PRNewswire\/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical significance on the\u00a0primary endpoint, which was defined as a difference in the proportion of participants progressing to the first occurrence … Continue reading \"Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-08T10:48:28+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/661014\/Eli_Lilly_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients","datePublished":"2021-04-08T10:48:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\/"},"wordCount":2327,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/661014\/Eli_Lilly_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\/","name":"Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/661014\/Eli_Lilly_Logo.jpg","datePublished":"2021-04-08T10:48:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/661014\/Eli_Lilly_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/661014\/Eli_Lilly_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-and-incyte-announce-results-from-the-phase-3-cov-barrier-study-of-baricitinib-in-hospitalized-covid-19-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/473470","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=473470"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/473470\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=473470"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=473470"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=473470"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}